Society of Hematologic Oncology Annual Meeting

Conference Coverage

Interactive Features

Pop Quiz

Which JAK Inhibitor Remains the Standard of Care in Myelofibrosis?

09/25/2025

Miranda Manier, BA

In an interview with Consultant360, Junaid Anwar, MD, a hematology-oncology fellow at UT Health Houston, reviewed the current evidence base for JAK inhibitors in myelofibrosis from a pooled analysis of five...

09/25/2025

Research Summaries

Conference Coverage

Long-Term Follow-Up Shows Continued Efficacy of Iomab B-Led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML

09/30/2024

Anthony Calabro, MA

In a long-term follow-up to SIERRA, a multicenter, randomized, controlled phase 3 study, researchers found that patients 55 years of age or older with active relapsed or refractory acute myeloid leukemia...

09/30/2024

Conference Coverage

Meta-Analysis: FLT3 Inhibitors vs Placebo for Patients With Acute Myeloid Leukemia

09/27/2024

Anthony Calabro, MA

Researchers who developed a meta-analysis of 19 randomized controlled trials found a statistically significant improvement in overall survival with sorafenib when compared with placebo for patients with...

09/27/2024

research summary

research summary

Venetoclax-Based Regimens Show Promising Efficacy, Safety Profile for Older Patients with AML

09/23/2024

Anthony Calabro, MA

Researchers conducted a meta-analysis examining the current evidence on the safety, efficacy, and predictive factors for venetoclax-based regimens in older adults with acute myeloid leukemia.

09/23/2024

Conference Coverage

Conference Coverage

Does Waiting for Mutational Test Results Delay Time to Treatment for Patients Newly Diagnosed With AML?

09/19/2024

Jessica Ganga

In this retrospective study, researchers assessed the turnaround time of mutational tests in patients with newly diagnosed acute myeloid leukemia (AML) and the time from diagnosis to treatment initiation....

09/19/2024

Conference Coverage

Intrathecal Methotrexate Effective In CSF Clearance, Improving Neurologic Symptoms In AML Patients With CNS Involvement

09/29/2023

Anthony Calabro, MA

Researchers retrospectively identified patients with CNS AML and evaluated several treatments and outcomes for this type of cancer at two large academic institutions.

09/29/2023

January 2026

Current Issue

January 2026